Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Degenerative Lesion of Articular Cartilage of Knee
Interventions: Episealer Knee System, Microfracture; Device · Procedure
Lead sponsor: Episurf Medical Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 8
States / cities: Tempe, Arizona • La Mesa, California • New Orleans, Louisiana + 5 more

Conditions: Neoplasms
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more

Conditions: Cellular Diagnosis, Prostate Cancer
Interventions: ClariCore Optical Biopsy System; Device
Lead sponsor: Precision Biopsy, Inc.; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Denver, Colorado • Baltimore, Maryland • New York, New York + 2 more

Conditions: Venous Leg Ulcers
Interventions: Apligraf; Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Anemia
Interventions: epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta (Mircera); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 17
States / cities: Hot Springs, Arkansas • Los Angeles, California • Riverside, California + 14 more

Conditions: Peripheral Vascular Disease
Interventions: Absolute Pro™ Peripheral Self-Expanding Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Anesthesia
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 5 Years to 15 Years
Enrollment: 1,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan

Conditions: Osteoarthritis
Interventions: Oral Salmon Calcitonin, Oral Salmon Calcitonin (Placebo); Drug
Lead sponsor: Nordic Bioscience A/S; Industry
Eligibility: 51 Years to 80 Years
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Tuscaloosa, Alabama • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Non-Muscle- Invasive Bladder Cancer
Interventions: Durvalumab, BCG; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Sorafenib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Uncomplicated Urinary Tract Infections
Interventions: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg, Phenazopyridine Hydrochloride Tables, USP 200 mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Port Jefferson, New York

Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Ibrutinib; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 15 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Columbus, Ohio

Conditions: Phenylketonurias
Interventions: NGGT002; Genetic
Lead sponsor: NGGT INC.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Orange, California • Minneapolis, Minnesota • Morristown, New Jersey + 2 more

Conditions: Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
Interventions: Savolitinib, Sunitinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 8
States / cities: La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Genital Warts, Perianal Warts
Interventions: NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Fountain Valley, California • Lomita, California • San Diego, California + 11 more

Conditions: Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer
Interventions: Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol; Device
Lead sponsor: Aroa Biosurgery Limited; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 7 more

Conditions: Brain Injury
Interventions: NeuroResource Facilitation (NRF); Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: New York, New York • Carlisle, Pennsylvania

Conditions: Prostate Cancer
Interventions: 225Ac-PSMA-R2, 68Ga-PSMA-R2, 68Ga-PSMA-11; Drug · Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 91
States / cities: Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more

Conditions: Distal Forearm Fractures
Interventions: Closed Reduction, Long Arm Fiberglass Cast, Short Arm Fiberglass Cast; Procedure · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 4 Years to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Down Syndrome, Alzheimer Disease, Dementia
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 25 Years to 55 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more

Conditions: Hypotension, Orthostatic
Interventions: midodrine hydrochloride (ProAmatine®); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: St. Petersburg, Florida • Upland, Pennsylvania • San Antonio, Texas

Conditions: Major Depressive Disorder
Interventions: DVS SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 33
States / cities: Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more

Search by objective public record fields.

Episealer® Knee System IDE Clinical Study

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.

CARE--Childhood Awareness and Recall Evaluation

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Study of COYA 302 for the Treatment of ALS

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

Savolitinib vs. Sunitinib in MET-driven PRCC.

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers

NRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE)

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Long Arm Vs Short Arm Fiberglass Cast for Treatment of Displaced Distal Radius Fractures

Trial-Ready Cohort-Down Syndrome (TRC-DS)

A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD